

Special Issue

The Issue of Multidrug-Resistant Pathogens in Nosocomial Infections, 2nd Edition

Message from the Guest Editor

Although the COVID-19 pandemic has demonstrated how emerging and re-emerging pathogens represent an existential menace to humankind, the issue of antimicrobial resistance (AMR) looms as the perennial threat of this century. The main setting where AMR unfolds is obviously the nosocomial setting. In many countries, there are alarming rates of multidrug-resistant (MDR), extensively drug-resistant (XDR), or difficult-to-treat (DTR) pathogens among both Gram-negative and Gram-positive bacteria. The robust knowledge of epidemiology, resistance mechanisms, and available therapeutic options against superbugs is crucial to guarantee the best management of patients affected by invasive infections produced by these pathogens. This Special Issues aims to collect reviews and original articles addressing these topics to offer new insights from different viewpoints: epidemiological, aetiological, diagnostic, prognostic, and therapeutic.

Guest Editor

Dr. Alberto Enrico Maraolo

Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy

Deadline for manuscript submissions

31 December 2025



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/198253

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)